Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Caridad M delaUz"'
Autor:
Christina Y. Miyake, Erica J. Lay, Cheyenne M. Beach, Scott R. Ceresnak, Caridad M. Delauz, Taylor S. Howard, Christopher M. Janson, Kate Jardine, Prince J. Kannankeril, Maina Kava, Jeffrey J. Kim, Leonardo Liberman, Scott L. Macicek, Tam Dam Pham, Terry Robertson, Santiago O. Valdes, Gregory Webster, Sara B. Stephens, Diana M. Milewicz, Mahshid Azamian, Saad A. Ehsan, Kimberly M. Houck, Claudia Soler-Alfonso, Kevin E. Glinton, Mustafa Tosur, Na Li, Weiyi Xu, Seema R. Lalani, Lilei Zhang
Publikováno v:
Heart rhythm. 19(10)
TANGO2 deficiency disorder (TDD) is an autosomal recessive disease associated with metabolic crisis, lethal cardiac arrhythmias, and cardiomyopathy. Data regarding treatment, management, and outcomes of cardiac manifestations of TDD are lacking.The p
Autor:
Christina Y Miyake, Saranya Srinivasan, Daniel Ostermayer, Dwayne Wolf, Jeffrey J Kim, Caridad M delaUz, Santiago O Valdes, Claudia Pedroza, Shaine A Morris, Keila N Lopez, Vinh V Tran, Eric J Lee, Dianna Milewicz, Paul E Sirbaugh
Publikováno v:
Circulation. 138
Background: Data regarding racial and ethnic differences in incidence and survival in pediatric cardiac arrest are unknown. In large cities, universal tracking of cardiac arrest is limited by multiple response centers fielding calls. This study was p
Autor:
Jamie A. Decker, Santiago O. Valdes, Philip J. Lupo, Jeffrey J. Kim, Christina Y. Miyake, Caridad M. delaUz, Brady S. Moffett
Publikováno v:
Cardiology in the young. 25(6)
Introduction: Digoxin or propranolol are used as first-line enteral agents for treatment of infant supraventricular tachycardia. We used a large national database to determine whether enteral digoxin or propranolol was more effciacious as first-line
Autor:
Philip J. Lupo, Santiago O. Valdes, Christina Y. Miyake, Caridad M. delaUz, Jeffrey J. Kim, Michele Krenek, Brady S. Moffett
Publikováno v:
Pediatric cardiology. 36(1)
Flecainide is frequently used for treatment of cardiac arrhythmias in children. Due to concerns regarding increased mortality, there has been hesitancy to use flecainide in children with congenital heart disease (CHD) or cardiomyopathy (CM). The obje